SC 13D/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

SCHEDULE 13D

(Rule 13d-101)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO
RULE 13d-2(a)
(Amendment No. 7)

BIOENVISION, INC.

(Name of Issuer)

COMMON STOCK, PAR VALUE $0.001

(Title of Class of Securities)

09059N 10 0

(CUSIP Number)

Steven H. Rouhandeh

SCO Capital Partners LLC

1285 Avenue of the Americas, 35^th Floor

New York, New York 10019
(212) 554-4158

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

July 11, 2007

(Date of Event Which Requires Filing This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box  q.

(Continued on following pages)

(Page 1 of 12)

SCHEDULE 13D

CUSIP No.  09059N 10 0
Page  2 of 12 Pages

This Schedule 13D Amendment No. 7 is being filed, among other things, to provide an update regarding SCO Capital Partners LLC’s position with respect to the Issuer’s proposed merger transaction with Genzyme Corporation. As more fully described in Item 4 below, on July 11, 2007, SCO Capital Partners LLC sent an additional letter to the Board of Directors of the Issuer setting forth in further detail SCO Capital Partners LLC’s position with respect to the transaction. A copy of the letter is attached hereto as Exhibit F.

SCHEDULE 13D

CUSIP No.  09059N 10 0
Page  3 of 12 Pages

1.	NAMES OF REPORTING PERSONS IRS IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) SCO Capital Partners LLC
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a)  [   ] (b)  [X]
3.	SEC USE ONLY
4.	SOURCE OF FUNDS (see instructions) OO
5.	CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) [   ]
6.	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware
NUMBER OF		7.	SOLE VOTING POWER 6,289,056
SHARES BENEFICIALLY OWNED		8.	SHARED VOTING POWER 231,942
BY EACH REPORTING		9.	SOLE DISPOSITIVE POWER 6,289,056
PERSON WITH		10.	SHARED DISPOSITIVE POWER 231,942
11.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 6,520,998
12.	CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions) [   ]
13.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11 11.8%
14.	TYPE OF REPORTING PERSON (see instructions) PN

SCHEDULE 13D

CUSIP No.  09059N 10 0
Page  4 of 12 Pages

1.	NAMES OF REPORTING PERSONS IRS IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) SCO Capital Partners, L.P.
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a)  [  ] (b)  [X]
3.	SEC USE ONLY
4.	SOURCE OF FUNDS* OO
5.	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) [  ]
6.	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware
NUMBER OF		7.	SOLE VOTING POWER 688,333
SHARES BENEFICIALLY OWNED		8.	SHARED VOTING POWER 0
BY EACH REPORTING		9.	SOLE DISPOSITIVE POWER 688,333
PERSON WITH		10.	SHARED DISPOSITIVE POWER 0
11.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 688,333
12.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* [  ]
13.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 1.3%
14.	TYPE OF REPORTING PERSON* PN

SCHEDULE 13D

CUSIP No.   09059N 10 0
Page  5 of 12 Pages

1.	NAMES OF REPORTING PERSONS IRS IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) SCO Securities LLC
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a)  [   ] (b)  [X]
3.	SEC USE ONLY
4.	SOURCE OF FUNDS (see instructions) OO
5.	CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) [   ]
6.	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware
NUMBER OF		7.	SOLE VOTING POWER 0
SHARES BENEFICIALLY OWNED		8.	SHARED VOTING POWER 0
BY EACH REPORTING		9.	SOLE DISPOSITIVE POWER 0
PERSON WITH		10.	SHARED DISPOSITIVE POWER 0
11.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 0
12.	CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions) [   ]
13.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11 0%
14.	TYPE OF REPORTING PERSON (see instructions) BD

SCHEDULE 13D

CUSIP No.  09059N 10 0
Page  6 of 12 Pages

1.	NAMES OF REPORTING PERSONS IRS IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) Steven H. Rouhandeh
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a)  [   ] (b)  [X]
3.	SEC USE ONLY
4.	SOURCE OF FUNDS (see instructions) OO
5.	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) [  ]
6.	CITIZENSHIP OR PLACE OF ORGANIZATION United States
NUMBER OF		7.	SOLE VOTING POWER 6,977,389
SHARES BENEFICIALLY OWNED		8.	SHARED VOTING POWER 231,942
BY EACH REPORTING		9.	SOLE DISPOSITIVE POWER 6,977,389
PERSON WITH		10.	SHARED DISPOSITIVE POWER 231,942
11.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 7,209,331
12.	CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions) [  ]
13.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11 13.4%
14.	TYPE OF REPORTING PERSON (see instructions) IN

SCHEDULE 13D

CUSIP No.  09059N 10 0
Page  7 of 12 Pages

Item 1. Security and Issuer.

This Amendment No. 7 to Schedule 13D (“Schedule 13D”) is being filed to amend Amendment No. 6 to Schedule 13D filed on July 3, 2007 with respect to the common stock, par value $.001 per share (the “Common Stock”) of Bioenvision, Inc., a Delaware corporation (“Bioenvision” or the “Company”). The principal executive offices of the Company are located at 345 Park Avenue, 41st Floor, New York, New York 10154.

This Schedule 13D, as amended, is being filed pursuant to Section 13(d) of the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder (the “Exchange Act”).

Item 2. Identity and Background.

(a) This Schedule 13D is filed by (i) Steven H. Rouhandeh (“Mr. Rouhandeh”), (ii) SCO Capital Partners LLC, a limited liability company organized under the laws of the State of Delaware (“SCO”), (iii) SCO Capital Partners, L.P., a limited partnership organized under the laws of the State of Delaware (“SCO LP”) and (iv) SCO Securities LLC, a limited liability company organized under the laws of the State of Delaware (“SCO Securities”). Mr. Rouhandeh, SCO, SCO LP and SCO Securities are collectively referred to herein as the “Reporting Persons.”

(b) The Reporting Persons’ business address is 1285 Avenue of the Americas, 35th Floor, New York, New York 10019.

(c) The principal business of Mr. Rouhandeh is to serve as the Chairman and managing member of SCO, managing member of the entity that serves as sole member of SCO Securities and managing member of the entity that serves as general partner of SCO LP. The principal business of SCO and SCO LP is to invest in biotechnology companies. The principal business of SCO Securities is to provide certain broker-dealer services to biotechnology companies.

(d) During the last five years, none of the Reporting Persons have been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

(e) During the last five years, none of the Reporting Persons have been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction that resulted in a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

(f) Mr. Rouhandeh is a United States citizen. SCO and SCO Securities are each a limited liability company organized under the laws of the State of Delaware. SCO LP is a limited partnership organized under the laws of the State of Delaware.

Item 3. Source and Amount of Funds or Other Consideration.

On June 15, 2007, SCO transferred to SCO LP 688,333 shares of Common Stock that SCO received upon exercise of SCO’s warrant to purchase Common Stock on May 1, 2007 (as described below). The transfer of these shares of Common Stock was exempt from registration under Regulation D promulgated under the Securities Act or Section 4(1) and 4(2) of the Securities Act.

On May 1, 2007, SCO exercised in full the warrant to purchase 688,333 shares of Common Stock that it received in connection with the Bioenvision’s May 8, 2002 private placement transaction (as described below). Pursuant to such warrant exercise, SCO received 688,333 shares of Common Stock at a purchase price of $1.50 per share which SCO paid in cash. The issuance of these shares of Common Stock was exempt from registration under Regulation D promulgated under the Securities Act or Section 4(2) of the

SCHEDULE 13D

CUSIP No.  09059N 10 0
Page  8 of 12 Pages

Securities Act. The source of funds for the warrant exercise was internal capital of an affiliated entity. As described above, SCO transferred such shares of Common Stock to SCO LP on June 15, 2007.

On November 1, 2006, SCO exercised in full the warrant to purchase 1,200,000 shares of Common Stock that it received in connection with Bioenvision’s November 16, 2001 revolving credit facility transaction (as described below). SCO exercised this warrant pursuant to a cashless exercise provision at a purchase price of $1.25 per share and received a total of 927,768 shares of Common Stock with the remaining 272,232 shares of Common Stock issuable pursuant to such warrant paid to Bioenvision in consideration of such exercise. The issuance of these shares of Common Stock was exempt from registration under Regulation D promulgated under the Securities Act or Section 4(2) of the Securities Act.

On November 1, 2006, SCO Securities exercised in full the warrant to purchase 90,000 shares of Common Stock that it received in connection with the execution of the engagement letter between SCO Securities and Bioenvision (as described below). SCO Securities exercised this warrant pursuant to a cashless exercise provision at a purchase price of $1.25 per share and received a total of 69,583 shares of Common Stock with the remaining 20,417 shares of Common Stock issuable pursuant to such warrant paid to Bioenvision in consideration of such exercise. On February 21, 2007, the 69,583 shares of Common Stock were transferred to SCO. The issuance of these shares of Common Stock was exempt from registration under Regulation D promulgated under the Securities Act or Section 4(2) of the Securities Act.

On November 1, 2006, the Sophie C. Rouhandeh Trust (the “SR Trust”) exercised in full the warrant that it received in connection with Bioenvision’s November 16, 2001 revolving credit facility transaction (as described below). The SR Trust exercised this warrant pursuant to a cashless exercise provision at a purchase price of $1.25 per share and received a total of 115,971 shares of Common Stock with the remaining 34,029 shares of Common Stock issuable pursuant to such warrant paid to Bioenvision in consideration of such exercise. The issuance of these shares of Common Stock was exempt from registration under Regulation D promulgated under the Securities Act or Section 4(2) of the Securities Act.

On November 1, 2006, the Chloe H. Rouhandeh Trust (the “CR Trust” and, together with the SR Trust, the “Trusts”) exercised in full the warrant that it received in connection with Bioenvision’s November 16, 2001 revolving credit facility transaction (as described below). The CR Trust exercised this warrant pursuant to a cashless exercise provision at a purchase price of $1.25 per share and received a total of 115,971 shares of Common Stock with the remaining 34,029 shares of Common Stock issuable pursuant to such warrant paid to Bioenvision in consideration of such exercise. The issuance of these shares of Common Stock was exempt from registration under Regulation D promulgated under the Securities Act or Section 4(2) of the Securities Act.

On May 14, 2004 and on March 22, 2004, upon closings of private placement financings pursuant to which SCO Securities acted as placement agent. As consideration for services rendered, Bioenvision issued to SCO Securities warrants to purchase an aggregate of 170,092 shares of Common Stock at an exercise price of $6.25 per share, subject to certain anti-dilution adjustments. SCO Securities allocated these warrants to SCO. The warrants expire five years from the date of issuance. The issuance of these warrants was exempt from registration under Regulation D promulgated under the Securities Act or Section 4(2) of the Securities Act. No cash consideration was paid by SCO or SCO Securities to the Company in connection with the issuance of these warrants.

On May 8, 2002, Bioenvision consummated a private placement transaction pursuant to which Bioenvision raised $17.75 million in equity financing. SCO Securities acted as Bioenvision’s financial advisor in connection with this equity offering. As consideration for services rendered, SCO received a warrant to purchase 688,333 shares of Common Stock at an exercise price of $1.50 per share. The warrants expire five years from the date of issuance. This warrant was exercised on May 1, 2007 as described above. The issuance of these warrants was exempt from registration under Regulation D

SCHEDULE 13D

CUSIP No.  09059N 10 0
Page  9 of 12 Pages

promulgated under the Securities Act or Section 4(2) of the Securities Act. No cash consideration was paid by SCO or SCO Securities to the Company in connection with the issuance of these warrants.

On February 1, 2002, Bioenvision issued an aggregate of 7,000,000 shares of Common Stock to the former stockholders of Pathagon, Inc., in connection with the consummation of a merger transaction. Of this amount, SCO received 5,121,613 shares of Common Stock as consideration in the merger transaction. The issuance of these shares was exempt from registration under Regulation D promulgated under the Securities Act or Section 4(2) of the Securities Act.

On November 16, 2001, Bioenvision and SCO entered into a revolving credit facility pursuant to which Bioenvision could borrow up to $1 million from SCO. In connection with this revolving credit facility, Bioenvision issued (i) to SCO a warrants to purchase 1,200,000 shares of Common Stock at an exercise price of $1.25 per share, subject to certain anti-dilution adjustments, and (ii) to each of the SR Trust and the CR Trust, with respect to both of which Mr. Rouhandeh, Chairman of SCO, serves as a trustee, a warrant to purchase 150,000 shares of Common Stock at an exercise price of $1.25 per share, subject to certain anti-dilution adjustments. All of the foregoing warrants expire five years from the date of issuance. All of these warrants were exercised by their respective holders on November 1, 2006 as described above. The issuance of these warrants was exempt from registration under Regulation D promulgated under the Securities Act or Section 4(2) of the Securities Act. As a trustee of the Trusts, Mr. Rouhandeh has shared voting power and shared investment power with respect to these shares, but disclaims any beneficial ownership thereof.

On November 16, 2001, Bioenvision entered into an engagement letter with SCO Securities pursuant to which SCO Securities acted as Bioenvision’s financial advisor. In connection with this engagement letter and services rendered pursuant thereto, Bioenvision issued to SCO Securities LLC, an affiliate of SCO, a warrant to purchase 90,000 shares of Common Stock at an exercise price of $1.25 per share, subject to certain anti-dilution adjustments. The warrant expires five years from the date of issuance. This warrant was exercised on November 1, 2006 as described above. The issuance of this warrant was exempt from registration under Regulation D promulgated under the Securities Act or Section 4(2) of the Securities Act.

Item 4. Purpose of Transaction.

Each of the Reporting Persons purchased their shares of Common Stock and warrants to purchase Common Stock for investment purposes. Each of the Reporting Persons may acquire additional shares of Common Stock from time to time, in open market purchases, negotiated transactions or otherwise, and may sell any or all of such shares of Common Stock at any time.

On May 29, 2007, Bioenvision announced that it had entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Genzyme Corporation, a Massachusetts corporation (“Genzyme”) and Wichita Bio Corporation, a Delaware corporation and a wholly-owned subsidiary of Genzyme (the “Purchaser”) pursuant to which the Purchaser will commence a tender offer for all of the outstanding shares of Common Stock and all of the outstanding shares of Series A Convertible Participating Preferred Stock of Bioenvision at a purchase price of $5.60 per share of Common Stock. The Reporting Persons do not believe that the purchase price adequately values Bioenvision. Consequently, based on the currently available information and terms, the Reporting Persons intend at this time not to tender their shares in connection with such transaction and not to vote in favor of such transaction if such vote is requested.

On May 29, 2007, SCO delivered a letter to Bioenvision’s board of directors outlining its objections to the transaction contemplated by the Merger Agreement. A copy of the letter is attached hereto as Exhibit A and is incorporated herein by reference.

SCHEDULE 13D

CUSIP No.  09059N 10 0
Page  10 of 12 Pages

On June 4, 2007, SCO delivered a second letter to Bioenvision’s board of directors providing further detail as to its objections to the transaction contemplated by the Merger Agreement. A copy of the letter is attached hereto as Exhibit B and is incorporated herein by reference.

On June 18, 2007, SCO delivered a third letter to Bioenvision’s board of directors providing further detail as to its objections to the transaction contemplated by the Merger Agreement. A copy of the letter is attached hereto as Exhibit C and is incorporated herein by reference.

On June 27, 2007, SCO delivered a fourth letter to Bioenvision’s board of directors providing further detail as to its objections to the transaction contemplated by the Merger Agreement. A copy of the letter is attached hereto as Exhibit D and is incorporated herein by reference.

On July 3, 2007, SCO delivered a fifth letter to Bioenvision’s board of directors providing further detail as to its objections to the transaction contemplated by the Merger Agreement. A copy of the letter is attached hereto as Exhibit E and is incorporated herein by reference.

On July 11, 2007, SCO delivered a sixth letter to Bioenvision’s board of directors providing further detail as to its objections to the transaction contemplated by the Merger Agreement. In addition, SCO has decided to exercise the prior rights that it reserved to appoint two members to the Bioenvision board of directors. A copy of the letter is attached hereto as Exhibit F and is incorporated herein by reference.

Other than as set forth in the preceding paragraphs of this Item 4, each of the Reporting Persons does not have any plans or proposals which relate to or would result in any of the matters enumerated in clauses (a) through (j), inclusive, of Item 4 of Schedule 13D, namely: (a) the acquisition by any person of additional securities of the Company or the disposition of securities of the Company; (b) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Company or any of its subsidiaries; (c) a sale or transfer of a material amount of assets of the Company or any of its subsidiaries; (d) any change in the present Board of Directors or management of the Company, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the Board; (e) any material change in the present capitalization or dividend policy of the Company; (f) any other material change in the Company’s business or corporate structure; (g) changes in the Company’s charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Company by any person; (h) causing a class of securities of the Company to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; (i) a class of equity securities of the Company becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Exchange Act; or (j) any action similar to any of those enumerated above.

Item 5. Interest in Securities of the Issuer.

(a) As of the date hereof, (i) each of the two Trusts owns 115,971 shares of Common Stock, (ii) SCO owns 6,118,964 shares of Common Stock, and warrants to purchase an aggregate of 170,092 shares of Common Stock, (iii) SCO LP owns 688,333 shares of Common Stock and (iv) SCO Securities owns no Common Stock or warrants to purchase Common Stock. These securities in the aggregate represent beneficial ownership of 13.4% of the outstanding Common Stock of Bioenvision as of May 3, 2007 (as set forth in its Form 10-Q filed on May 9, 2007). In his capacity as Chairman and managing member of SCO and in his capacity as managing member of the entity that serves as general partner of SCO LP, Mr. Rouhandeh may be deemed beneficially to own the 6,807,297 shares of Common Stock and warrants to purchase 170,092 shares of Common Stock owned directly by SCO and SCO LP.

(b) As a trustee of each Trust, Mr. Rouhandeh has shared power with his brother and spouse to vote 231,942 shares of Common Stock held by the Trusts. Mr. Rouhandeh, in his capacity as Chairman and managing member of SCO and in his capacity as managing member of the entity that serves as general partner of SCO LP, has the sole power to direct the vote and disposition of the 6,807,297 shares of

SCHEDULE 13D

CUSIP No.  09059N 10 0
Page  11 of 12 Pages

Common Stock owned by SCO and SCO LP and, upon conversion of warrants, Mr. Rouhandeh has the sole power to direct the vote and disposition of an additional 170,092 shares of Common Stock underlying warrants owned by SCO. SCO, SCO LP and SCO Securities disclaim beneficial ownership of the warrants held by the Trusts.

(c) Reference is made to the Reporting Persons’ responses to Item 3.

(d) Not applicable.

(e) Not applicable.

Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.

Reference is made to the Reporting Persons’ responses to Item 3.

Item 7. Material to be Filed as Exhibits.

Exhibit A	—	May 29, 2007 Letter from SCO Capital Partners LLC to the Board of Directors of Bioenvision, Inc.(1)
Exhibit B	—	June 4, 2007 Letter from SCO Capital Partners LLC to the Board of Directors of Bioenvision, Inc. (2)
Exhibit C	—	June 18, 2007 Letter from SCO Capital Partners LLC to the Board of Directors of Bioenvision, Inc. (3)
Exhibit D	—	June 27, 2007 Letter from SCO Capital Partners LLC to the Board of Directors of Bioenvision, Inc. (4)
Exhibit E	—	July 3, 2007 Letter from SCO Capital Partners LLC to the Board of Directors of Bioenvision, Inc. (5)
Exhibit F	—	July 11, 2007 Letter from SCO Capital Partners LLC to the Board of Directors of Bioenvision, Inc.

(1) Incorporated by reference to Schedule 13D Amendment No. 2 filed by the Reporting Persons on May 30, 2007.

(2) Incorporated by reference to Schedule 13D Amendment No. 3 filed by the Reporting Persons on June 5, 2007.

(3) Incorporated by reference to Schedule 13D Amendment No. 4 filed by the Reporting Persons on June 18, 2007.

(4) Incorporated by reference to Schedule 13D Amendment No. 5 filed by the Reporting Persons on June 27, 2007.

(5) Incorporated by reference to Schedule 13D Amendment No. 6 filed by the Reporting Persons on July 3, 2007.

SCHEDULE 13D

CUSIP No.  09059N 10 0
Page  12 of 12 Pages

SIGNATURES

After reasonable inquiry and to the best of each of our knowledge and belief, we certify that the information set forth in this statement is true, complete and correct.

Dated: July 11, 2007

SCO CAPITAL PARTNERS LLC
By:	/s/ Steven H. Rouhandeh
	Steven H. Rouhandeh Chairman

SCO SECURITIES LLC
By:	/s/ Steven H. Rouhandeh
	Steven H. Rouhandeh Chairman

SCO CAPITAL PARTNERS, L.P. By: SCO Capital Investors LLC
By:	/s/ Steven H. Rouhandeh
	Steven H. Rouhandeh Managing Member

/s/ Steven H. Rouhandeh

Steven H. Rouhandeh

EX-99.(F)

SCO CAPITAL PARTNERS LLC

July 11, 2007

Board of Directors

Bioenvision, Inc.

345 Park Avenue, 41^st Floor

New York, New York 10154

Bioenvision Board Members:

With this letter, we put forth a new plan for Bioenvision and its shareholders who have recently rejected a takeover by Genzyme by an overwhelming majority. We strongly believe that SCO’s plan is in the best interest of shareholders, and will unlock significant unrealized value in Bioenvision and the clofarabine asset specifically. The SCO plan involves the following steps:

• SCO To Fill Two Bioenvision Board Seats: SCO has reserved its prior rights to put two candidates on the board of directors of Bioenvision, and with this letter we inform you of our desire to exercise those rights immediately. Additionally, we expect the resignation of the Perseus-Soros/Aislings employees on the board, who have already sold their entire interest in Bioenvision, and believe that Bioenvision should evaluate the remaining board members on a case-by-case basis, to provide some continuity for corporate governance purposes.

• Stabilize and Augment Management: For the sake of continuity during the approval process for clofarabine in Adult AML in Europe, SCO believes Bioenvision should retain key employees while seeking to augment key management positions with qualified clinical, regulatory and business development expertise.

• Terminate the Genzyme Sub-License to Clofarabine in North America: Bioenvision should immediately terminate its sublicense agreement with Genzyme based upon numerous breaches for which it has reserved its rights. These breaches include: (1) Failure to file in the US in acute leukemias by fixed deadlines set out in the Co-Development Agreement, for which Bioenvision reserved its rights, (2) failure to file NDAs in chronic leukemias and solid tumors by fixed deadlines in the Co-Development Agreement, (3) failure to reimburse approximately $10 million in R&D expenses as required by the Co-Develpoment Agreement, and (4) failure to share clinical data, despite continued requests, in accordance with the Co-Development Agreement. We believe that Genzyme has materially breached both the letter and spirit of the Co-Development Agreement.

1285 AVENUE OF THE AMERICAS, 35TH FLOOR, NEW YORK, NEW YORK 10019

Telephone: 212-554-4158   Fax: 212-554-4058

Bioenvision should terminate the sub-license agreement immediately, continue to seek regulatory approvals in Europe and in the US for clofarabine in adult AML, and then to re-initiate a process to seek new marketing partners in the US and throughout the world.

• Seek Exit Through Partnerships or an Appropriately Run Auction or Sales Process: With additional approvals in the US and Europe, we believe that Bioenvision would be well positioned to hire an independent investment bank and initiate, within the next six to twelve months, a well-run process to market the company to possible acquirors.

Again, we applaud Bioenvision’s common shareholders for flatly rejecting the inadequate $5.60 tender offer from Genzyme. We believe that the aforementioned framework of a strategic plan will more fully realize the value of Bioenvision and its clofarabine asset for our fellow common shareholders. We encourage patience and perseverance while we strive to achieve value for shareholders.

Sincerely,

/s/ Steven H. Rouhandeh

Steven H. Rouhandeh

1285 AVENUE OF THE AMERICAS, 35TH FLOOR, NEW YORK, NEW YORK 10019

Telephone: 212-554-4158   Fax: 212-554-4058